Abstract
Sodium oxybate (γ-hydroxybutyrate, GHB) is an endogenous GHB/GABAB receptor agonist, clinically used to promote slow-wave sleep and reduce next-day sleepiness in disorders such as narcolepsy and fibromyalgia. The neurobiological signature of these unique therapeutic effects remains elusive. Promising current neuropsychopharmacological approaches to understand the neural underpinnings of specific drug effects address cerebral resting-state functional connectivity (rsFC) patterns and neurometabolic alterations. Hence, we performed a placebo-controlled, double-blind, randomized, cross-over pharmacological magnetic resonance imaging study with a nocturnal administration of GHB, combined with magnetic resonance spectroscopy of GABA and glutamate (Glu) in the anterior cingulate cortex (ACC). Sixteen healthy male volunteers received 50mg/kg GHB p.o. or placebo at 02:30am to maximize deep sleep enhancement and multi-modal brain imaging was performed at 09:00am of the following morning. Independent component analysis of whole-brain rsFC revealed a significant increase of rsFC between the salience network (SN) and the right central executive network (rCEN) after GHB intake compared to placebo. This SN-rCEN coupling was significantly associated with changes in GABA and GABA/Glu levels in the ACC (pall<0.05). The proposed framework allows to identify a neural pattern of pharmacological modulation of the SN, which may serve as a neurobiological signature of the wake-promoting effects of GHB.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT02342366
Funding Statement
All authors report no conflicts of interest, financial or otherwise. The study was supported by grants from the Swiss National Science Foundation (SNSF) to HPL (grant # 320030_163439) and the Clinical Research Priority Program Sleep & Health of the University of Zurich.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Swiss Agency for Therapeutic Products (Swissmedic) as well as by the Ethics Committee of the Canton of Zurich.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
